财务数据和关键指标变化 - 公司Q2营收为111亿欧元,同比增长3%,受汇率不利影响约2.4亿欧元 [29] - EBITDA为21亿欧元,同比下降16%,主要受到不利的产品组合影响和短期激励计提增加 [29][30] - 核心每股收益为0.94欧元,同比下降23% [30] - 经营活动产生的自由现金流为13亿欧元,同比改善 [31] 各条业务线数据和关键指标变化 作物科学 - 销售额50亿欧元,同比增长1%,受到玉米种植面积下降、天气不利和仿制品价格压力的影响 [32][33][34] - EBITDA为5.24亿欧元,同比大幅下降,受到不利的产品组合和短期激励计提增加的影响 [34] - 但通过成本控制和价格管理部分抵消了这些不利因素 [34] 医药 - 销售额增长4%,价格上涨3%,量增1% [35] - 新品牌如Nubeqa和Kerendia表现强劲,抵消了Xarelto销售下滑 [35][36][37] - Xarelto销售下降11%,受专利到期和仿制药竞争的影响 [37] - EBITDA下降4%,受到Xarelto销售下滑、汇率不利影响和短期激励计提增加的影响 [38] 消费者健康 - 销售额增长5%,几乎所有品类都实现增长 [39] - 消化系统健康品类增长15%,过敏和感冒品类下降 [39] - EBITDA为3.14亿欧元,利润率21.5% [39] 各个市场数据和关键指标变化 - 中国市场整体表现良好,医药业务受到VBP政策影响已基本消化 [69] - 拉丁美洲市场作物科学业务有望在下半年表现强劲,受益于大豆和新产品的增长 [80][81] 公司战略和发展方向及行业竞争 - 公司在医药、作物科学和消费者健康三大业务板块均有创新和发展计划 [12][13][24] - 医药管线进展顺利,包括Kerendia、Nubeqa等新品的临床试验和商业化 [20][21][22][23][24] - 作物科学业务推出短株玉米和新一代VT4 Pro玉米等创新产品 [12][13] - 消费者健康业务计划扩大Iberogast等品牌在美国的销售 [13] - 公司正在系统推进组织精简和扁平化,提升敏捷性和客户导向 [18][19] - 在农药相关诉讼方面,公司取得一些积极进展,并计划通过立法等方式进一步化解风险 [14][15][16][17] 管理层对经营环境和未来前景的评论 - 尽管农业市场环境充满挑战,但公司作物科学业务仍能基本抵消不利因素 [8] - 医药业务保持良好势头,新品牌如Nubeqa和Kerendia表现出色 [9][10] - 消费者健康业务有望在下半年加速增长,但成本压力仍存在 [11][44] - 公司有信心在下半年进一步提升业绩,实现全年目标 [26][27][28] 其他重要信息 - 公司正积极推进诉讼和立法方面的工作,以化解相关风险 [14][15][16][17][87][88] - 公司正在系统推进组织精简和扁平化,提升敏捷性和客户导向 [18][19] 问答环节重要的提问和回答 问题1 **Vincent Andrews 提问** 询问2025年玉米种植面积和市场份额预期 [47][48] **Rodrigo Santos 回答** 公司预计2025年玉米种植面积和市场份额仍将保持强劲,但具体数据需要等到第三季度报告时更新 [48][49][80][81] 问题2 **Peter Verdult 提问** 询问Kerendia心力衰竭临床试验结果与其他同类药物的比较 [51][52] **William N. Anderson 回答** 公司对Kerendia的临床试验结果充满信心,将在欧洲心脏病学大会上发布详细数据,与其他同类药物相比具有一定优势 [52] 问题3 **Sachin Jain 提问** 询问Xarelto销售下滑趋势和医药业务毛利率展望 [56][57][58][59] **Stefan Oelrich 回答** Xarelto销售下滑趋势将在下半年加剧,但公司新品牌如Nubeqa和Kerendia有望抵消这一影响。医药业务毛利率短期内或将承压,但中期目标仍为20%左右 [58][59]

Bayer AG (BAYRY) reported second-quarter 2024 core earnings of 25 cents per American Depositary Receipt (ADR), on par with the Zacks Consensus Estimate. The company reported earnings of 33 cents per ADR in the year-ago quarter. Core earnings of €0.94 per share deteriorated 23% year over year due to a decline in earnings at the Crop Science Division. Total sales in the reported quarter were $12 billion (€11.14 billion), up 0.9% on a reported basis as volume growth of 1.6% and positive pricing impact of 1.5% ...

业绩总结 - 拜耳集团2024年上半年销售增长1%，核心每股收益为3.76欧元，自由现金流为-14亿欧元[3] - 2024年第二季度净销售额为111亿欧元，同比增长3%（按货币和组合调整后增长1%），EBITDA为21亿欧元，EBITDA利润率为18.9%[8] - 2024年上半年净销售额为249亿欧元，同比下降2%[26] - 2024年第二季度核心净收入为9亿欧元，同比下降25%[17] - 2024年第二季度EBITDA为17亿欧元，同比下降26%[17] - 2024年上半年EBITDA为3,373百万欧元，EBITDA利润率为26.2%[39] - 2024年上半年整体EBIT为1,834百万欧元，较去年同期的1,853百万欧元有所下降[39] 用户数据 - 农作物科学部门销售增长-1%，制药部门增长4%，消费者健康部门增长2%[4] - 2024年第二季度，农作物保护核心业务销售额为49.81亿欧元，增长1%（按货币和组合调整后）[9] - 制药部门第二季度销售额为45.57亿欧元，同比增长4%（按货币和组合调整后）[10] - 消费者健康部门第二季度销售额为14.66亿欧元，同比下降6%（按货币和组合调整后）[11] - 2024年上半年，Crop Science部门的销售额为12,888百万欧元，同比下降2.9%[39] 未来展望 - 2024年全年集团展望确认，预计净销售额在-1%到+3%之间，EBITDA（特殊项目前）预计下降9%到3%[14] - 2024年核心每股收益预计在5.10到5.50欧元之间，较2023年下降[14] - 2024年自由现金流预计在20亿到30亿欧元之间[14] - 预计2024年草甘膦价格将下降，但销量恢复将部分抵消这一影响[22] - 全球需求强劲，2024年预计将恢复正常的采购模式[23] 新产品和新技术研发 - Nubeqa在全球的销售增长率为90%，在美国市场的表现尤为突出[54] - 公司在心血管疾病领域的多个项目正在推进，包括心衰和糖尿病相关的治疗[51] - 2024年中期前预计将有多个重要的研发里程碑，包括HER2/mEGFR抑制剂的临床进展[53] - 新型除草剂的潜在销售额预计为€5亿，预计到2032年可实现30%的销售潜力[49] - 新型杀虫剂的潜在销售额约为€2亿，预计到2032年可实现30%的销售潜力[49] 市场扩张和并购 - 公司在2024年第二季度的销售潜力（PSP）预计达到约€11亿，主要来自于玉米和大豆的基因组升级项目[48] - 玉米LEP5第二代种子密度的数字工具在EMEA市场的潜在销售额约为€11亿[48] - 大豆的本土抗性年更新项目的潜在销售额约为€5亿[48] - 小麦年更新项目的潜在销售额约为€5亿[48] 负面信息 - 2024年第二季度核心每股收益同比下降10%[26] - Xarelto的销售额为1,625百万欧元，同比下降22%[32] - Consumer Health部门的销售额为2,890百万欧元，同比下降5%[39] - Adalat的销售额受到中国VBP政策的持续影响[33]

Bayer (BAYRY) announced that it has met the primary endpoint of radiological progression-free survival (rPFS) in its late-stage study evaluating the safety and efficacy of darolutamide in combination with androgen deprivation therapy (ADT) without docetaxelin patients with metastatic hormone-sensitive prostate cancer (mHSPC).The phase III ARANOTE study enrolled 669 patients who were randomized to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT.Per the data readout, the combo ...

Bayer (BAYRY) announced that its wholly owned and independently operating subsidiary, Asklepios BioPharmaceutical, Inc. (AskBio), initiated recruitment in the mid-stage study REGENERATE-PD.REGENERATE-PD is a phase II study evaluating the efficacy and safety of AB-1005, an investigational adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease.Subjects will receive either bilateral image-guided infusion of AAV2-GD ...

Bayer AG [BAYZF] Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Jost Reinhard - IR Conference Call Participants Emily Field - Barclays Vincent Andrews - Morgan Stanley Peter Verdult - Citibank Richard Vosser - J.P. Morgan Joel Jackson - BMO Capital Markets Florent Cespedes - ...

Bayer AG (BAYRY) reported first-quarter 2024 core earnings of 77 cents per American Depositary Receipt (ADR). The company reported earnings of 79 cents per ADR in the year-ago quarter.Core earnings of €2.82 per share declined 4.4% year over year.Total sales in the reported quarter were $14.95 billion (€13.77 billion), down 4.3% on a reported basis. On a currency and portfolio-adjusted basis, sales declined 0.6% year over year.All growth rates mentioned below are on a year-over-year basis after adjusting for ...

///////////// Health for all, Hunger for none | --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company an ...

Bayer AG (BAYRY) announced positive top-line results of the phase III study, OASIS 3, evaluating the efficacy and long-term safety of pipeline candidate elinzanetant compared to placebo.Elinzanetant, a dual neurokinin-1,3 (NK-1,3) receptor antagonist, is in late-stage clinical development for the non-hormonal treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, administered orally once daily.OASIS 3 is the third phase III study in the OASIS clinical development program. The st ...

Bayer AG (BAYRY) reported fourth-quarter 2023 core earnings of 50 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 45 cents. The company reported earnings of 34 cents per ADR in the year-ago quarter.Core earnings of €1.85 per share rose 37% year over year in the fourth quarter of 2023.Total sales in the reported quarter were $12.77 billion (€11.86 billion), down 1.2% on a reported basis. On a currency and portfolio-adjusted basis, sales rose 5.5% year over year.All gro ...